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Abstract 
Background 
Induction of immune tolerance by an increase in regulatory T-cells (T-regs) following 
extracorporeal photopheresis (ECP) is thought to contribute to how ECP exerts its 
therapeutic effect in patients with chronic graft-versus-host disease (cGvHD). We 
investigated whether percentages and absolute counts of T-regs changed post-ECP, 
and examined correlation with response. 
 
Methods 
Absolute counts and % of CD4+ T cells and T-regs 
(CD4+CD25+FOXP3+CD127dim/-) were evaluated using flow cytometry in 32 
patients with cGvHD treated by ECP for a minimum of 3 months (m), and up to 12m. 
CD4+ or T-regs at baseline to 12m post-ECP were compared to changes in skin 
disease scores or global organ involvement, or the ability to taper steroids, at 14, 28, 
and 56wk.  
 
Results 
T-reg % increased significantly above any overall changes in CD4+ % at 6, 9, and 
12m post-ECP. There was no statistically significant association between T-regs and 
skin or steroid response, whereas a larger increase in CD4+ count from baseline to 
1-3m corresponded to increased odds of being able to reduce steroid dose E\ 
at 14wk. Skin and global organ responders at 28wk had higher median T-reg counts 
3m post-ECP than non-responders, as did steroid responders at 56wk who were 
12m post-ECP.   
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Conclusions 
T-reg counts and % varied greatly amongst cGvHD patients, and the increase post-
ECP was not significant until 6m. No clear correlation was found between T-regs and 
clinical improvement, suggesting that increases in T-reg numbers &/or proportions 
are not driving the mechanism leading to a response following ECP. 
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INTRODUCTION 
Chronic graft-versus-host disease (cGvHD) is an immunological disorder that 
remains a major cause of morbidity and mortality following allogeneic haematopoietic 
stem cell transplantation (HSCT). It involves alloreactivity of donor T cells to host 
histocompatibility antigens, which can affect many sites, such as the skin, mucous 
membranes, liver and lungs. Corticosteroids and immunosuppressive drugs are 
common treatments for cGvHD, but the resulting unpredictable and variable 
response rates, toxicities and profound immunodeficiency, can cause deaths from 
infection. Extracorporeal photopheresis (ECP) is used as a safe and efficacious 
treatment for some immune-mediated diseases such as steroid-refractory cGvHD, 
following on from its development in 1987 for use in treating cutaneous T-cell 
lymphoma. Clinical improvement in cGvHD patients treated with ECP enables 
tapering or discontinuation of immunosuppressive agents and corticosteroids. As T- 
and B-cell responses to novel and recall antigens are not destroyed by ECP, it brings 
a reduced risk of infection compared to the use of immunosuppressive drugs1. 
 
ECP is an apheresis therapy that involves centrifugal separation and collection of 
white blood cells (WBC) from blood, with the return of red blood cells (RBC) and 
plasma to the patient. The photosensitising agent, 8-methoxypsoralen (8-MOP) is 
administered to the collected WBC, followed by circulation through an irradiation 
chamber, where exposure to ultraviolet-A radiation occurs. The photoactivated 8-
MOP causes cross-linking of DNA in cell nuclei, inducing apoptosis of the treated 
WBC, which are then reinfused to the patient. Apoptotic cells express specific 
membrane proteins which are recognised by receptors on antigen-presenting cells 
(APC) in the circulation. The full effects of ECP on the immune system remain poorly 
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understood, but it is thought that returning apoptosing WBC to the patient induces 
immune tolerance by modulating APC, switching their activity in favour of anti-
inflammatory cytokine production, whilst decreasing production of pro-inflammatory 
cytokines, and inducing regulatory T cells (T-regs)2. 
 
T-regs are a subpopulation of T cells which can derive from the thymus (natural T-
reg), or be induced in peripheral lymphoid organs (induced T-reg)3. T-regs can 
suppress effector T cell responses and the activity of other immune cells, such as 
dendritic, and B cells. The balance between effector T cell and T-reg populations is 
critical in achieving proper control of the quality and extent of adaptive immune 
responses, for establishing self-tolerance, and intolerance to non-self- antigens. T-
regs are CD4+ cells that express high levels of CD25 (the interleukin (IL)-2 receptor 
Į-chain) and the transcription factor, forkhead box protein-3 (FOXP3). FOXP3 is a 
key regulator of T-reg development and function. Non-regulatory T cells can also 
express the intracellular marker FOXP3, so a more stringent definition of T-regs 
incorporates an additional marker of high specificity. T-regs downregulate expression 
of the IL-UHFHSWRUĮ-chain (CD127) compared to conventional T cells, so a 
CD127dim/- marker is also often used for T-reg characterisation4.  
 
The ability of T-regs to suppress aberrant immune responses, regulate T cell 
homeostasis, and to maintain self-tolerance, prompted interest in their impact on 
cGvHD, and how ECP might influence their numbers5. Evidence that T-regs play a 
key role in GvHD was demonstrated in a mouse model where removal of the 
CD4+CD25+ T cells present in the stem cell graft accelerated GvHD, and adding 
freshly isolated CD4+CD25+ T cells at the time of HSCT delayed, or even prevented, 
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this disease6. Administration of cultured and activated CD4+CD25+ T-regs was 
shown to inhibit GvHD lethality in mice7. Striking results in murine GvHD, coupled 
with the ready availability of donor T-regs, has led to GvHD prevention emerging as 
the first clinical application for human T-reg8. Evidence for treating existing GvHD 
with T-regs remains sparse, however, but an anecdotal report suggested 
amelioration of cGvHD in one patient following transfer of in vitro expanded donor T-
regs9.  
 
The potential impact of T-regs in ECP was observed when established experimental 
GvHD was reversed in mice by increasing donor T-regs as a consequence of 
transferring splenocytes from ECP-treated animals10. T-regs whose development is 
promoted during ECP are antigen-specific, corresponding to the clones of cytotoxic 
T-cells that were collected in the apoptotic WBC product after predominating in the 
circulation during an active immune response2. Using a hypersensitivity model in 
mice, Maeda and colleagues showed that antigen-specific T-regs were induced by 
apoptotic cells generated from ECP, and that transferring these T-regs to other 
syngeneic mice created the same antigen-specific immune suppression11.  
 
Despite frequent suggestions that T-regs play an integral part in the mode of action 
of ECP when used to treat cGvHD patients, reported levels of T-regs in this disease 
remain inconclusive. Compared to HSCT recipients without cGvHD, both an 
increase12, 13, and a decrease14, 15, in T-regs have been documented in cGvHD. A 
study of 29 HSCT patients reported that a numerical deficit of T-regs following HSCT 
was associated with acute, but not chronic, GvHD16, whereas a different study 
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reported elevated T-reg numbers and percentages in both acute and chronic 
GvHD17.  
 
There is a paucity of studies reporting the effects of ECP on T-reg numbers and 
proportions in cGvHD patients. We performed a study of 32 patients, using flow 
cytometry to determine changes in CD4+ T-cell and T-reg numbers and proportions 
after a minimum of 3 months (m) ECP treatment, and examined how these cell 
measures correlated with skin and global organ responses, and the ability to taper 
steroids. Here, we report that T-reg numbers increase statistically significantly post-
ECP above any overall change in CD4+ T-cells, and that these T-reg increases are 
not a universal feature of response to ECP. This is the largest study to date that 
comprehensively examines the effect of ECP on T-reg numbers and their association 
with clinical improvement in cGvHD patients.  
 
MATERIALS AND METHODS 
Study Population 
Adult patients (n=32, 50% male, aged 19-62, median=46.5 years) diagnosed with 
cGvHD provided written consent and were included in the study, subject to the 
inclusion and exclusion criteria detailed in Table 1. At ECP start, 78% of patients had 
skin involvement, and 91% were on steroids. Patient characteristics are detailed in 
7DEOH(&3ZDVSHUIRUPHGXVLQJWKH7+(5$.26&(//(;® or UVAR XTS® 
Photopheresis Systems at the Photopheresis Unit, Rotherham NHS Foundation 
Trust.  Patients received 2 treatments over 2 consecutive days (1 cycle) every 
fortnight for 14wk, then 1 cycle every 4wk, although some variation did occur (see 
Table 1). The study period was 56wk: all 32 patients were treated for a minimum of 
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PIRUPIRUPDQGSDWLHQWVZHUHWUHDWHGIRUP5HDVRQVIor 
stopping ECP in the 6 patients that received ECP for <12m include death from 
infections (n=4), an unscheduled stop (n=1) and cGvHD improvement (maximal 
response) (n=1). Peripheral blood (PB) samples were taken every month 
immediately before each treatment cycle commenced. PB was also collected from 
25 age-matched healthy volunteers, who gave informed consent, to enable 
comparison with patient CD4+ T-cell counts and %. The study was approved by York 
Research Ethics Committee, and internally by the R&D Department.  
 
Measures of Response to ECP 
Clinical response scores were obtained at 14, 28, and 56wk post-ECP, where 
possible. SKIN: The modified Rodnan scoring system was used to evaluate skin 
disease, where a high score equates to more severe skin disease and the % 
reduction in skin score from baseline was used to calculate response. Patients with a 
0-24% reduction in skin score were classed as non-responders, whereas responders 
experienced a 25-100% reduction from pre-ECP values. STEROIDS: The ability to 
reGXFHVWHURLGGRVHPJNJE\ZKLOVWGLVHDVHDFWLYLW\ZDVFRQWUROOHGRU
improved by ECP, was considered a response. Patients whose steroids were 
tapered only 0-49%, or received an increased dose, were considered non-
responders. GLOBAL ORGAN: Global organ response was derived based on 
changes in the level of involvement of the main organ affected (skin, gut, liver, eyes, 
mucous membranes, or lung), using the response definition detailed above for skin, 
and the 2005 National Institutes of Health (NIH) cGvHD Consensus Response 
Criteria18 for all other organs. For our analyses, either a partial or complete 
response, as detailed by the NIH response definitions, were considered to be a 
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global organ response. Non-responders were defined according to the criteria for 
organ progression. 
 
Flow Cytometry of CD4+ Cells and T-regs 
Fresh anti-coagulated PB samples were used for enumeration of CD4+ T-cells. 
CD4+ T-cells were identified following incubation of 100µl PB at 4°C for 30 min with 
anti-human antibodies as follows: CD4 conjugated with phycoerythrin-cyanine 7 (PE-
Cy7); PE-Texas Red (energy-coupled dye, ECD)-conjugated CD45; and CD3-PE 
anti-human antibodies. All antibodies were from Beckman Coulter (BC) 
(Buckinghamshire, UK), except CD4-PE-Cy7 (BD Biosciences, Oxford, UK). RBC 
were lysed with IOTest® 3 Lysing Solution (BC) after antibody staining of WBC. 
 
For enumeration of T-regs, intracellular labelling was required. Mononuclear cells 
ZHUHILUVWVHSDUDWHGIURPIUHVK3%VDPSOHVXVLQJ/\PSKR3UHSGHQVLW\JUDGLHQt 
medium (Axis-6KLHOG3R&$61RUZD\DFFRUGLQJWRWKHPDQXIDFWXUHU¶V
recommendation, and washed 2 times with RPMI-1640 medium (Sigma-Aldrich, 
Dorset, UK). Cells were labelled for cell surface markers by incubating 100µl cell 
preparation at 4°C for 30 min with anti-human antibodies: CD127 conjugated with 
IOXRUHVFHLQLVRWKLRF\DQDWH),7&%'3KDUPLQJHQ2[IRUG8.&'-PE-Cy5 
(BC); CD4-PE-Cy7; and CD45-ECD. Labelled cells were subsequently washed with 
cold 0.9% NaCl solution, fixed and permeabilised using a kit (Miltenyi, Surrey, UK) 
DFFRUGLQJWRWKHPDQXIDFWXUHU¶VSURWRFRODQGLQWUDFHOOXODUVWDLQLQJSHUIRUPHGXVLQJ
an anti-human FOXP3-PE antibody (Miltenyi). Cells were resuspended in 500µl 
0.9%NaCl solution prior to analysis. 
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T-regs were identified by the phenotypic expression profile 
CD4+CD25+FOXP3+CD127dim/-. The frequencies (%) of lymphocytes that were 
CD3+CD4+, and the % of CD3+CD4+ T-cells that were T-regs were evaluated using 
five-colour flow cytometry on an FC-500 Flow Cytometer (BC), following gating of 
lymphocytes according to CD45 expression and side-scatter. Absolute counts 
(cells/µl) of CD3+CD4+ T cells were calculated by multiplying their % by the 
lymphocyte count, obtained by automated differential using an Advia® 2120i 
Haematology System (Siemens, Germany). T-reg counts were derived by multiplying 
their % by the count of CD3+CD4+ T-cells.  
 
Statistical Analysis 
All analyses were performed using SPSS (PASW) 20 software. Multiple analyses 
(see SDC, Materials and Methods) were performed to address the following 
questions: 
 - Are there statistically significant differences in:  
1. T-regs/CD4 of prior acute and non-prior acute GvHD patients? 
2. CD4 measures of healthy controls and cGvHD patients? 
3. T-regs/CD4 with duration of ECP treatment? 
4. T-regs/CD4 of responders and non-responders? 
 - Are there associations between: 
5. The number or % of T-regs/CD4 and clinical response? 
6. The change of T-reg/CD4 measures from pre-ECP to post-ECP levels, and 
clinical response? 
7. T-reg/CD4 measures and skin or steroid scores? 
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RESULTS 
Response rates of the study group 
To establish whether our patient cohort gave results that were representative of 
previously established response rates, we examined the skin, steroid, and global 
organ response at the last measured time point PIRUHDFKSDWLHQW)RXU
(12.5%) patients had died by 8m of commencing ECP. Of the 26 patients that had 
skin involvement, 65.4% undergoing ECP achieved at least a 25% improvement in 
skin scores. Similarly, 60% of the 30 patients on steroids demonstrated a response 
WR(&3ZKHUHDGRVHUHGXFWLRQZDVDFKLHYHG*OREDORUJDQUHVSRQGHUV
accounted for 71.9% of the 32 patients in our cohort. Our response rates were 
comparable to the study of 32 cGvHD patients by Apisarnthanarax et al., who found 
64% achieved DVWHURLGGRVHUHGXFWLRQ19, and to a study by Couriel et al. of 71 
patients with severe cGvHD, where overall improvement was seen in 61%, with 59% 
of patients achieving a skin response20. 
 
Prior acute GvHD 
No statistically significant differences were found in T-reg or CD4+ measures 
between patients that had acute GvHD prior to their cGvHD, and those that did not.  
 
Differences in CD4+ measures between cGvHD patients and healthy controls 
Patients with cGvHD had statistically significantly lower CD4+ % and counts at 
baseline (P<0.001) and at the last measured time point post-ECP (P<0.001), than 
the healthy control group. 
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Changes in the proportion of T-reg/CD4+ cells with ECP treatment duration  
After accounting for overall changes in CD4+ measures, there was a statistically 
significant increase in T-reg measures over time (P=0.01). Compared to pre-ECP 
measures, there were statistically significant increases of T-reg proportions at 6m 
(P=0.003), 9m (P=0.008), and 12m (P=0.02). Median T-reg count increased 3.7-fold 
at 9m from the pre-ECP value. No statistically significant change in CD4+ % 
(P=0.111) or count (P=0.165) was found over time (Figure 1). 
 
Associations between T-reg/CD4+ measures and clinical response 
No statistically significant associations were found between T-reg/CD4+ counts or % 
DQGDVNLQGLVHDVHVFRUHUHGXFWLRQRIRUWKHDELOLW\WRWDSHUVWHURLGVE\ 
 
Differences in the distribution of T-regs/CD4 between responders and non-
responders  
Skin response 
At 28wk, patients demonstrating a skin response had statistically significantly 
different distributions of T-reg counts at 3m post-ECP (P=0.025), with a higher 
median, than non-responders (7.7 vs 3.1cells/µl) (Figure 2). Skin responders at 56wk 
had lower medians than non-responders (PRI&'DW-9m post-ECP 
(SDC, Figure 1); and CD4+ counts at 1 & 9m (SDC, Figure 2).   
 
Steroid response 
Patients demonstrating a steroid response at 56wk had higher median counts of T-
regs (P=0.009) (Figure 2) and CD4+ (P=0.027) (SDC, Figure 2) at 12m post-ECP. 
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Global organ response 
At 28wk, patients demonstrating a reduction in global organ involvement had 
statistically significantly different distributions, with higher medians, of T-reg counts 
at 3m post-ECP than non-responders (P=0.023) (Figure 2), but similar T-reg % 
(SDC, Figure 3). At 56wk, responders had lower median: CD4+ % at 0-2 and 6m 
(P6'&)LJXUH1); and CD4+ counts at 1m (P=0.024) (SDC, Figure 2). 
 
Associations between response and the post-ECP changes at 1-12m in T-
reg/CD4+ measures from pre-ECP values  
Skin response 
No association was found between post-ECP changes in T-reg or CD4+ measures 
DQGDQLPSURYHPHQWLQVNLQGLVHDVHRI 
 
Steroid response 
No association was found between post-ECP changes in T-reg measures and the 
ability to taper steroids. For the CD4+ analyses, after controlling for pre-ECP CD4+ 
count and platelet count, a 1 cell/µl increase in the difference between pre-ECP and 
1, 2, and 3m CD4+ counts increased the odds of a steroid response at 14wk (1m 
odds ratio (OR) 1.0067, confidence interval (CI): 1.0002-1.0132, P=0.043; 2m OR 
1.0100, CI: 1.0002-1.0198, P=0.045; 3m OR 1.009, CI: 1.001-1.016, P=0.027). 
Similar results were found for 3m CD4+ counts with cyclosporine as a covariate (OR 
1.008, CI: 1.001-1.016, P=0.028).   
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Associations between T-reg/CD4+ measures and skin scores 
Moderate positive associations were observed between pre-ECP T-reg counts and 
baseline skin scores (higher T-reg counts associated with greater skin disease) 
(P=0.025) (SDC, Figure 4a), or 14wk (P=0.034). Moderate positive associations 
were also seen between skin scores at 56wk and CD4+ % at pre-ECP (P=0.042), 
1m (P=0.019), 2m (P=0.036), 3m (P=0.008), 6m (P=0.006) and 9m (P=0.008), and 
CD4+ counts at 1m (P=0.047) and 9m (P=0.023). 
  
Associations between T-reg/CD4+ measures and steroid dose  
Lower T-reg counts at 12m were associated with higher steroid dose at 56wk and, 
therefore, greater disease activity (negative association, P=0.009)(SDC, Figure 5a). 
A higher pre-ECP T-reg %, however, was positively associated with greater baseline 
steroid dose (P=0.016)(SDC, Figure 5b), whereas lower pre-ECP CD4+ counts were 
associated with greater baseline steroid dose (P=0.003). Similarly, lower 3m CD4+ 
counts were associated with higher 14wk steroid dose (negative association, 
P=0.033) (SDC, Figure 5c).   
 
DISCUSSION 
Our study of 32 cGvHD patients treated with ECP revealed a statistically significant 
increase in T-regs from baseline at 6m post-ECP and beyond, which is at variance 
with some previous reports. Rao and colleagues, for example, did not find a 
statistically significant difference in T-regs in 11 cGvHD patients for their study 
duration of 0-6m post-ECP21. Our results also conflict with the study of 27 cGvHD 
patients by Di Biaso and colleagues, who reported a statistically significant increase 
in T-regs at the sixth ECP cycle (approximately 3m post-ECP), but not thereafter. 
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This study also found that only cGvHD patients who responded to ECP 
demonstrated an increase in circulating T-reg numbers22, whereas we found no clear 
pattern, with some non-responders showing an increase in numbers and/or 
proportion of T-regs, and some responders whose T-reg counts decreased or 
remained static.  
 
We conducted a high number of tests that led to the issue of multiple testing. Caution 
should be applied when interpreting results as the more tests performed, the more 
likely it is to obtain a false positive result.   
 
Interestingly, no statistically significant increase in median CD4+ T-cell count or % 
was found, even after 12m of ECP (Figure 1e-h). Both pre- and post-ECP CD4+ 
counts were statistically significantly lower in cGvHD patients compared to healthy 
controls. Our study indicates that ECP did not normalise CD4+ T-cell numbers, 
which conflicts with the findings of Bladon & Taylor23, who found an enhancement of 
CD4+ T-cell numbers after 3m of ECP in their study of 8 cGvHD patients.  
 
The functionality of T-regs was not tested in our study, and it is important to consider 
that the T-regs we measured may be dysfunctional or possess an elevated 
suppressive quality, thereby affecting their potential to influence immune responses 
in a greater or lesser capacity. Indeed, ECP has been shown to augment 
immunosuppressive T-reg function by triggering CD39-mediated adenosine 
production by T-reg, which can reduce T-cell proliferation24. T-regs can, therefore, 
become more suppressive after ECP, but augmentation of adenosine production is 
only one of a number of mechanisms that operate during T-reg-mediated 
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suppression. The variety of impairment that may occur in cGvHD of other 
suppressive mechanisms, such as: the release of IL-10 &/or transforming growth 
factor-ȕ7*)-ȕFRQVXPSWLRQRI,/-2; and the expression of inhibitory molecules16, 
may account somewhat for our heterogeneous observations that patients with low or 
high T-reg counts or % demonstrated a clinical response.  
 
Our analysis of T-reg numbers and proportion in cGvHD patients has shown a high 
degree of variability. A heterogeneous study population complicates the 
interpretation of results, with T-reg reconstitution and clinical response being 
influenced by patient characteristics, stem cell source, T cell depletion strategy of the 
graft, infections, underlying disease, extent of tissue injury, and immunosuppressive 
medications25. Changes in T-reg frequencies can be either drug-induced, or disease-
related, and it is important to remember that drug use varies as ECP progresses. 
Intravenous immunoglobulin expands T-regs26, calcineurin inhibitors used to treat 
GvHD decrease T-reg numbers, whereas sirolimus use produces an increase, and 
corticosteroids are known to enhance expression of FOXP3 and improve the survival 
and function of T-regs27. The cytokine milieu in which T-regs operate can also affect 
their function. For example, tumour necrosis factor (TNF) downmodulates the 
function of CD4+CD25+ T-regs28, and TGF-ȕLQGXFHV)2;3H[SUHVVLRQ29. 
 
In an attempt to resolve the debate as to the importance of T-regs in clinical 
response to ECP, we not only looked at associations of response with T-reg counts 
and %, but also investigated if it was the change in T-reg measures post-ECP that 
might be pivotal. Furthermore, associations between T-reg measures and skin and 
steroid scores were examined. From all these analyses, the conclusion of no clear 
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associations between T-reg measures and clinical improvement is drawn. Consistent 
with our findings, Nord et al. found in her study of 16 cGvHD patients, who were 
treated with ECP for a minimum of 3m, that increases in the proportion of T-regs 
were not always accompanied by clinical benefit30. Any significant impact of T-regs 
on the clinical improvement of patients with cGvHD following ECP may be qualitative 
rather than quantitative, rendering observations based solely on the quantity of T-
regs of limited use. Furthermore, if there is no deficit of T-regs in cGvHD, as several 
studies have suggested12, 13, it is unlikely that simply boosting peripheral blood (PB) 
T-reg numbers will be sufficient to generate complete amelioration. A better 
understanding of the diversity of T-reg subsets, plasticity, and function in the context 
of ECP therapy and cGvHD is required, with a greater focus on their role in target 
organs. A greater force than PB T-regs alone is likely to be needed to suppress the 
chronic inflammatory process at work in cGvHD, involving cellular and humoral 
responses, cytokines, and chemokine expression in target tissues. 
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Table 1: Patient Characteristics 
cGvHD Patient Characteristics  n=32  
Inclusion criteria  
x  \HDUVROGIRUWKLVVWXG\. 
x Patients must require second-line/third-line salvage therapy because of 
either steroid-refractory or steroid-dependent cGvHD. Steroid- refractory 
is defined as minimal, or no, response to prednisolone 1mg/kg or 
equivalent after a minimum of 4 wks of treatment; steroid-dependent is 
defined as the inability to reduce steroids to < 10 mg or equivalent daily 
without flare of cGVHD. Alternatively, patients must be unable to tolerate 
standard first-line corticosteroid therapy. 
x Patients must have cGvHD primarily affecting at least one of the 
IROORZLQJRUJDQVVNLQPXFRVDOPHPEUDQHVPRXWKDQG»RUH\HGLVHDVH
liver. 
x Patients should have cGVHD confirmed with compatible histology from 
an affected organ biopsy, wherever possible.  
x Patients with cGvHD following full-intensity conditioning transplants, 
reduced-intensity conditioning transplants or donor lymphocyte infusions 
are all eligible.  
 
Exclusion criteria  
x Patients exhibiting a known sensitivity to psoralen compounds.  
x Patients with comorbidities that may result in photosensitivity.  
x Patients with aphakia.  
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x < 40 kg in weight (defined by machine characteristics).  
x Pregnancy.  
x History of heparin-induced thrombocytopenia.  
x Uncontrolled infection.  
x Absolute neutrophil count < 1.0 x109/L.  
x Platelet count < 20 x109/L despite platelet transfusion support.  
x Diarrhoea > 1000 mL daily.  
x Other cause thought likely to cause inability to tolerate apheresis 
procedure.  
Age, years: Median (Range) 46.5     (19-62) 
Sex M/F % (no.) 50:50   (16:16) 
Diagnosis 
Acute myeloid leukaemia 
Acute lymphoblastic leukaemia 
Chronic myeloid leukaemia 
Non-+RGJNLQ¶VO\PSKRPD 
Chronic lymphocytic leukaemia 
Myeloma 
Myelodysplastic syndrome 
+RGJNLQ¶VO\PSKRPD 
 
8 
6 
5 
4 
3 
3 
2 
1 
Donor 
Related donor, % (no.) 
Matched donor, % (no.) 
 
50         (16) 
50         (16) 
Preparative regimen  
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Myeloablative, %  (no.) 
Reduced intensity conditioning, %  (no.) 
47         (15)  
53         (17) 
NIH Score at ECP Onset 
Mild, % (no.) 
Moderate, % (no.) 
Severe, % (no.) 
 
12.5        (4) 
50          (16) 
37.5       (12) 
Organ target at GvHD onset % (no.) 
Skin only 
Gut only 
Liver only 
Eyes only 
Multiple:  
Skin + 1 of respiratory, joints, gut, liver, mucous membranes 
Skin + 2 of respiratory, joints, gut, liver, mucous membranes 
Skin + 3 (eyes, gut, liver) 
Skin + 4 of respiratory, joints, gut, liver, mucous membranes, 
eyes 
Gut + eyes 
Gut + 2 (joints, eyes) 
Gut + 3 (joints, liver, respiratory) 
 
25            (8) 
3.125       (1)          
6.25         (2) 
3.125       (1) 
 
 25            (8) 
18.75        (6) 
3.125        (1) 
6.25          (2) 
 
3.125        (1) 
3.125        (1) 
3.125        (1) 
Prior acute GvHD 
Yes    % (no.) 
No      % (no.) 
 
69            (22) 
31            (10) 
Time from Transplant to cGvHD 
Months: Median  (Range)              
 
3.7    (1.2-98.5) 
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Time from Transplant to ECP Start 
Months: Median  (Range)              
 
19.8 (3.2-133.8) 
Time from cGvHD Diagnosis to ECP Start  
Months: Median  (Range)              
 
11.8   (0.8-91) 
Platelet Count at ECP Start 
109/L: Median (Range) 
 
240.5   (21-614) 
Bilirubin Score at ECP Start 
µmol/L: Median (Range) 
 
12    (2-282) 
Drugs received at ECP Start 
Intravenous Immunoglobulin,  %   (no.)  
Prednisolone, % (no.) 
Cyclosporine, % (no.) 
Tacrolimus, % (no.) 
Mycophenolate mofetil (MMF), % (no.) 
Azathioprine (AZA), % (no.) 
Thalidomide, % (no.)  
Total Number of Immunosuppressive Agents Per Patient at    
      ECP Start: Median (Range) 
  
3       (1) 
90.6  (29) 
56.3  (18) 
12.5  (4) 
40.6  (13) 
0       (0)  
3.1    (1) 
 
2     (1-4) 
Number of ECP Treatments Per Patient Included in the 56wk 
Assessment Period 
2 treatments per ECP cycle = 16 treatments after fortnightly 
ECP from start to the 14wk assessment point; 24 treatments 
to the 28wk assessment (ECP cycles are every 4wk after 
14wk); and ~38 treatments to the 56wk assessment. 
Actual Treatments Received: Median (Range)  
  
 
 
 
 
 
35.5 (10-49) 
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Expected Treatments: Median (Range)  38     (16-38) 
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Figure 1- Absolute counts of: (a) T-regs; and (e) CD4+ cells, and proportions 
of: (b) CD4+ cells that are T-regs; and (f) lymphocytes that are CD4+ cells, at 
pre-ECP, and 1, 2, 3, 6, 9, and 12 months post-ECP. Fold-change from pre-
ECP to 1-12m post-ECP of (c) T-reg counts, (d) T-reg %, (g) CD4+ counts 
and (h) CD4+ %. Coloured lines in (a), (b), (e), and (f) represent values for 
individual patients, and the bold black lines in (a-h) show the medians. A 
statistically significant increase from pre-ECP levels of the proportion of T-
regs (after accounting for any changes in CD4+ count) was seen at 6, 9 and 
12 m post-ECP (b&d). Pre- and post-ECP CD4+ counts (e) and proportions (f) 
did not differ significantly. 
 
Figure 2 - Comparison of T-reg cells/µl at 0-12m post-ECP in patients with 
and without a response in: (a) skin; (b) steroids; and (c) global organ, as 
measured at 14, 28, and 56 weeks. Plots show medians in 25-75th percentile 
boxes, or median only if nZLWK-95th percentile range whiskers. The 
number (n) of patients in each group at each time point is given below the 
boxes. Outliers are shown as circles. Statistically significant (P <0.05) 
differences between responders (grey) and non-responders (white) are 
labelled with their Mann-Whitney P values. Tests were not done if n<4 in any 
group. 
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Figure 1: Changes in T-reg and CD4+ Absolute Counts and Proportions at 0-12m Post-ECP
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SDC, Materials and Methods 
 
Statistical Analysis 
Two-tailed significance was held at 5%. For the logistic regression, statistical 
significance was also conditional on 95% confidence intervals not including 1. There 
is no general consensus on what procedure to adopt for multiple comparisons1. 
Despite the large number of multiple tests carried out for this study, Bonferroni 
corrections were not used to aid the interpretation of the results. As recommended by 
Altman, we report unadjusted P-values and confidence limits with a suitable 
cautionary note on interpretation. The following 7 questions were addressed: 
 
1. Are there statistically significant differences in T-regs/CD4 between prior 
acute and non-prior acute GvHD patients? 
Mann-Whitney U-Tests were used to compare the distribution of T-reg or 
CD4+ measures between patients that had prior acute GvHD, with those that 
had not.  
 
2. Are there statistically significant differences in CD4 measures between 
healthy controls and cGvHD patients? 
An independent-samples t-test was conducted to compare patient CD4+ 
measures pre-ECP or at the last time point available post-ECP, with healthy 
control CD4+ measures. The data were log-transformed for this analysis, as it 
was not normally distributed. 
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3. Are there statistically significant changes in T-regs/CD4 with duration of 
ECP treatment? 
A longitudinal model was constructed to test whether there were any 
statistically significant changes in CD4+ cells or T-regs over time, accounting 
for changes in CD4+ by using the proportion of T-regs over CD4+. Cell 
proportions were log-transformed and comparisons made between the 
proportion measured at each time point, and the pre-ECP proportion.  
 
4. Is the number or % of T-regs/CD4 associated with clinical response? 
A logistic regression was used to assess whether the absolute count or % of 
T-regs or CD4+ cells pre-ECP and at 1-12m post-ECP were associated with 
skin response or the ability to taper steroids at 14, 28, and 56wk. Covariates 
included were either platelet count or treatment with cyclosporine, as these 
were found to influence response. The pre-ECP CD4+ or T-reg measure was 
also included in models if it was a statistically significant predictor when tested 
as the main independent variable. Baseline skin score or steroid dose was 
added as an additional covariate for analysis with skin or steroid response as 
the outcome. These analyses considered only the response status of the 
patient at the specific time point in question. 
 
5. Are there statistically significant differences in T-regs/CD4 between 
responders and non-responders? 
To investigate differences in the distribution of T-reg/CD4+ measures between 
responders and non-responders (skin, steroid and global organ) at each time 
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point, Mann-Whitney U-Tests were used where there were at least 4 
observations in any group. 
 
6. Are there associations in the change of T-reg/CD4 measures from pre-
ECP to post-ECP levels, and clinical response? 
Logistic regression was used to investigate associations between the change 
in T-reg and CD4 measures from pre-ECP to 1-12m post-ECP (calculated by 
subtracting the baseline), and skin or steroid responses, after accounting for 
baseline cell measures, and platelet count or cyclosporine use. Baseline skin 
score or steroid dose was added as an additional covariate for analysis with 
skin or steroid response as the outcome. 
 
7. Are there associations between T-reg/CD4 measures and skin or steroid 
scores? 
6SHDUPDQ¶VFRUUHODWLRQVZHUHXVHGWRWHVWWKe association between raw T-reg 
or CD4+ measures and skin or prednisolone scores.   
 
References 
1. Altman DG, Machin D, Bryant TN, et al. Statistics with confidence (2nd Ed.). 
London, UK: BMJ, 2000. 
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SDC, Figure 1 - Comparison of CD4+ proportions at 0-12m post-ECP in patients with and without a response in: (a) skin; (b) steroids; and (c) global 
organ, as measured at 14, 28, 56 and 112 weeks. Plots show medians in 25-75th percentile boxes, or median only if nZLWK-95th percentile range 
whiskers. The number (n) of patients in each group at each time point is given below the boxes. Outliers are shown as circles. Statistically significant (P 
<0.05) differences between responders (grey) and non-responders (white) are labelled with their Mann-Whitney P values. Tests were not done if n<4 in 
any group. 
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SDC, Figure 2 - Comparison of CD4+ cells/µl at 0-12m post-ECP in patients with and without a response in: (a) skin; (b) steroids; and (c) 
global organ, as measured at 14, 28, 56 and 112 weeks. Plots show medians in 25-75th percentile boxes, or median only if nZLWK-95th 
percentile range whiskers. The number (n) of patients in each group at each time point is given below the boxes. Outliers are shown as 
circles. Statistically significant (P <0.05) differences between responders (grey) and non-responders (white) are labelled with their Mann-
Whitney P values. Tests were not done if n<4 in any group. 
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SDC, Figure 3 - Comparison of T-reg proportions (%) at 0-12m post-ECP in patients with and without a response in: (a) skin; (b) steroids; 
and (c) global organ, as measured at 14, 28, 56 and 112 weeks. Plots show medians in 25-75th percentile boxes, or median only if nZLWK
5-95th percentile range whiskers. The number (n) of patients in each group at each time point is given below the boxes. Outliers are shown as 
circles. Mann-Whitney tests were not done if n<4 in any group. No statistically significant differences between respond7ers (grey) and non-
responders (white) were found. 
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SDC, Figure 4 ± Scatter plot series of skin scores at pre-ECP and 14, 28 & 56wk post-ECP and corresponding time point values of: (a) T-reg 
counts (black squares); (b) T-reg % (white squares); (c) CD4+ counts (black tULDQJOHVDQGG&'ZKLWHWULDQJOHV6SHDUPDQ¶V
correlation was used to test the association between T-reg/CD4+ counts or % and skin scores. Statistically significant (P<0.05) correlations 
are labelled with their P values, with greater pre-ECP T-reg counts associated with higher skin scores (worse response) at baseline (a) and 
14wk (not shown).  
 41 
0 1 0 2 0 3 0 4 0
0 .0
0 .5
1 .0
1 .5
2 .0
T -re g  c e lls /u lD a y  0
P
re
-
E
C
P
 
S
te
ro
id
 
D
o
s
e
 
(m
g/
kg
 
bo
dy
 
w
e
ig
ht
)
0 2 0 4 0 6 0
0 .0
0 .5
1 .0
1 .5
2 .0
T -re g  c e lls /u l 3 m
14
w
k 
S
te
ro
id
 
D
o
s
e
 
(m
g/
kg
 
bo
dy
 
w
e
ig
ht
)
0 1 0 2 0 3 0 4 0
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
T -re g  c e lls /u l 6 m
28
w
k 
S
te
ro
id
 
D
o
s
e
 
(m
g/
kg
 
bo
dy
 
w
e
ig
ht
)
0 1 0 2 0 3 0 4 0
0 .0
0 .2
0 .4
0 .6
T -re g  c e lls /u l 1 2 m
56
w
k 
S
te
ro
id
 
D
o
s
e
 
(m
g/
kg
 
bo
dy
 
w
e
ig
ht
)
0 5 1 0 1 5 2 0 2 5
0 .0
0 .5
1 .0
1 .5
2 .0
T -re g  % D a y  0
P
re
-
E
C
P
 
S
te
ro
id
 
D
o
s
e
 
(m
g/
kg
 
bo
dy
 
w
e
ig
ht
)
0 1 0 2 0 3 0 4 0
0 .0
0 .5
1 .0
1 .5
2 .0
T -re g  %  3 m
14
w
k 
S
te
ro
id
 
D
o
s
e
(m
g/
kg
 
bo
dy
 
w
e
ig
ht
)
0 5 1 0 1 5 2 0
0 .0
0 .2
0 .4
0 .6
0 .8
T -re g  %  6 m
28
w
k 
S
te
ro
id
 
D
o
s
e
(m
g/
kg
 
bo
dy
 
w
e
ig
ht
)
0 5 1 0 1 5
0 .0
0 .2
0 .4
0 .6
T -re g  %  1 2 m
56
w
k 
S
te
ro
id
 
D
o
s
e
(m
g/
kg
 
bo
dy
 
w
e
ig
ht
)
0 5 0 0 1 0 0 0 1 5 0 0
0 .0
0 .5
1 .0
1 .5
2 .0
C D 4 +  c e lls /u l  D a y  0
P
re
-
E
C
P
 
S
te
ro
id
 
D
o
s
e
 
(m
g/
kg
 
bo
dy
 
w
e
ig
ht
)
0 1 0 0 0 2 0 0 0 3 0 0 0
0 .0
0 .5
1 .0
1 .5
2 .0
C D 4 +  c e lls /u l  3 m
14
w
k 
S
te
ro
id
 
D
o
s
e
(m
g/
kg
 
bo
dy
 
w
e
ig
ht
)
0 5 0 0 1 0 0 0 1 5 0 0
0 .0
0 .2
0 .4
0 .6
0 .8
C D 4 +  c e lls /u l  6 m
28
w
k 
S
te
ro
id
 
D
o
s
e
(m
g/
kg
 
bo
dy
 
w
e
ig
ht
)
0 5 0 0 1 0 0 0 1 5 0 0
0 .0
0 .2
0 .4
0 .6
C D 4 +  c e lls /u l 1 2 m
56
w
k 
S
te
ro
id
 
D
o
s
e
 
(m
g/
kg
 
bo
dy
 
w
e
ig
ht
)
0 2 0 4 0 6 0 8 0
0 .0
0 .5
1 .0
1 .5
2 .0
C D 4 +  %  D a y  0
P
re
-
E
C
P
 
S
te
ro
id
 
D
o
s
e
 
(m
g/
kg
 
bo
dy
 
w
e
ig
ht
)
0 2 0 4 0 6 0 8 0
0 .0
0 .5
1 .0
1 .5
2 .0
C D 4 +  %  3 m
14
w
k 
S
te
ro
id
 
D
o
s
e
 
(m
g/
kg
 
bo
dy
 
w
e
ig
ht
)
0 2 0 4 0 6 0 8 0
0 .0
0 .2
0 .4
0 .6
0 .8
1 .0
C D 4 +  %  6 m
28
w
k 
S
te
ro
id
 
D
o
s
e
(m
g/
kg
 
bo
dy
 
w
e
ig
ht
)
0 2 0 4 0 6 0
0 .0
0 .2
0 .4
0 .6
C D 4 +  %  1 2 m
56
w
k 
S
te
ro
id
 
D
o
s
e
(m
g/
kg
 
bo
dy
 
w
e
ig
ht
)
a
b
c
d
M o d e ra te  P o s itiv e
P = 0 .0 1 6
M o d e ra te  N e g a tiv e
P = 0 .0 0 9
S D C , F ig u re  5 : A s s o c ia tio n s  b e tw e e n  T -re g /C D 4 +  A b s o lu te  C o u n ts /%  a n d  S te ro id  D o s e
P re -E C P  a n d  a t  3 , 6  & 1 2 m  P o s t-E C P
M o d e ra te  N e g a tiv e
P = 0 .0 3 3
M o d e ra te  N e g a tiv e
P = 0 .0 0 3
 
SDC, Figure 5 ± Scatter plot series of steroid dose at pre-ECP and 14, 28 & 56wk post-ECP and corresponding time point values of: (a) T-
reg counts (black squares); (b) T-reg % (white squares); (c) CD4+ counts EODFNWULDQJOHVDQGG&'ZKLWHWULDQJOHV6SHDUPDQ¶V
correlation was used to test the association between T-reg/CD4+ counts or % and steroid dose. Statistically significant (P<0.05) correlations 
are labelled with their P values. A greater steroid dose pre-ECP was associated with a higher pre-ECP T-reg % (b), but lower pre-ECP CD4+ 
counts (c). A greater steroid dose (worse response) at 56wk, however, was associated with lower T-reg counts at 9-12m post-ECP (a).  
 
